Pediatric Systemic Lupus Erythematosus

  • Earl D. Silverman


SLE is often associated with a prolonged partial thromboplastin time (PTT) because of the presence of a lupus anticoagulant (Chapter 16, Antiphospholipid Syndrome). However, in approximately 5% of lupus patients, there is also a prolonged prothrombin time (PT). The implications of a prolonged PT in lupus are altogether different. A prolonged PT in lupus is generally the result of an acquired deficiency of factor II or an acquired inhibitor to factor II. Patients with these defects generally present with hemorrhage rather than thrombosis, the hematological event normally linked with lupus anticoagulants. The treatment approach to an acquired factor II deficiency or inhibitor is immunosuppression. Prednisone is the only medication required in most circumstances, and high doses of this medication (e.g., 1–2 mg/kg/day) usually lead to a rapid normalization of the PT (Eberhard et al. 1992; Hudson et al. 1997; Massengill et al. 1997; Taddio et al. 2007).


Rheumatic Fever Lupus Anticoagulant Macrophage Activation Syndrome Congenital Heart Block Prolonged Prothrombin Time 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Avcin T, Benseler SM, et al A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum 2008; 59(2):206–213PubMedCrossRefGoogle Scholar
  2. Boros CA, Spence D, et al Hydrocephalus and macrocephaly: New manifestations of neonatal lupus erythematosus. Arthritis Rheum 2007; 57(2):261–266PubMedCrossRefGoogle Scholar
  3. Brik R, Padeh S, et al Systemic lupus erythematosus in children in Israel. Harefuah 1995; 129(7–8):233–235, 296, 295PubMedGoogle Scholar
  4. Brucato A, Frassi M, et al Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: A prospective study of 100 women. Arthritis Rheum 2001; 44(8):1832–5PubMedCrossRefGoogle Scholar
  5. Cabanas F, Pellicer A, et al Central nervous system vasculopathy in neonatal lupus erythematosus. Pediatr Neurol 1996; 15(2):124–126PubMedCrossRefGoogle Scholar
  6. Carhuapoma JR, Mitsias P, et al Cerebral venous thrombosis and anti-cardiolipin antibodies. Stroke 1997; 28(12):2363–2369PubMedCrossRefGoogle Scholar
  7. Castellino G, Padovan M, et al Single photon emission computed tomography and magnetic resonance imaging evaluation in SLE patients with and without neuropsychiatric involvement. Rheumatology (Oxford) 2008; 47(3):319–323CrossRefGoogle Scholar
  8. Cervera R, Asherson RA, et al Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 1997; (3):203–212Google Scholar
  9. Chung AB Fas N. Successful acyclovir treatment of herpes simplex type 2 hepatitis in a patient with systemic lupus erythematosus: A case report and meta analysis. Am J Med Sci 1998; 316(6):404–407PubMedCrossRefGoogle Scholar
  10. Cimaz R, Spence DL, et al Incidence and spectrum of neonatal lupus erythematosus: A prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr 2003; 142(6):678–683PubMedCrossRefGoogle Scholar
  11. Contreras G, Pardo V, Baudouin L, Lenz O, Tozman E, O'Nan P, Roth D. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350(10):971–980PubMedCrossRefGoogle Scholar
  12. Costedoat-Chalumeau N, Amoura Z, et al Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum 2004; 50(10):3187–3194PubMedCrossRefGoogle Scholar
  13. Dooley MA, Hogan S, et al Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997; 51(4):1188–1195PubMedCrossRefGoogle Scholar
  14. ###.
    Dror Y, Blachar Y, et al Systemic lupus erythematosus associated with acute Epstein-Barr virus infection. Am J Kidney Dis 1998; 32(5): 825–828PubMedCrossRefGoogle Scholar
  15. Eberhard A, Couper R, et al Exocrine pancreatic function in children with systemic lupus erythematosus. J Rheumatol 1992; 19(6):964–967PubMedGoogle Scholar
  16. Figueroa F, Berrios X, et al Anticardiolipin antibodies in acute rheumatic fever. J Rheumatol 1992; 19(8):1175–1180PubMedGoogle Scholar
  17. Flower C, Hennis A, et al Lupus nephritis in an Afro-Caribbean population: Renal indices and clinical outcomes. Lupus 2006; 15(10):689–694PubMedCrossRefGoogle Scholar
  18. Gladman G, Silverman ED, et al Fetal echocardiographic screening of pregnancies of mothers with anti-Ro and/or anti-La antibodies. Am J Perinatol 2002; 19(2):73–80PubMedCrossRefGoogle Scholar
  19. High WA Costner MI. Persistent scarring, atrophy, and dyspigmenta-tion in a preteen girl with neonatal lupus erythematosus. J Am Acad Dermatol 2003; 48(4):626–628PubMedCrossRefGoogle Scholar
  20. Hirose I, Ymamaguchi H, et al Fatal varicella infection in a girl with systemic lupus erythematosus after oral acyclovir prophylaxis. Eur J Pediatr 2006; 165(4):280–281PubMedCrossRefGoogle Scholar
  21. Hudson N, Duffy CM, et al Catastrophic haemorrhage in a case of pae-diatric primary antiphospholipid syndrome and factor II deficiency. Lupus 1997; 6(1):68–71PubMedCrossRefGoogle Scholar
  22. Inoue K, Fukushige J, et al Central nervous system vasculopathy associated with neonatal lupus. Pediatr Neurol 2002; 26(1):68–70PubMedCrossRefGoogle Scholar
  23. Jaeggi ET, Hamilton RM, et al Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years. J Am Coll Cardiol 2002; 39(1):130–137PubMedCrossRefGoogle Scholar
  24. Jennings JE, Sundgren PC, et al Value of MRI of the brain in patients with systemic lupus erythematosus and neurologic disturbance. Neuroradiology 2004; 46(1):15–21PubMedCrossRefGoogle Scholar
  25. Julkunen H, Kaaja R, et al Immune-mediated congenital heart block (CHB): Identifying and counseling patients at risk for having children with CHB. Semin Arthritis Rheum 1998; 28(2):97–106PubMedCrossRefGoogle Scholar
  26. Kasapcopur O, Ergul Y, et al Systemic lupus erythematosus due to Epstein-Barr virus or Epstein-Barr virus infection provocating acute exacerbation of systemic lupus erythematosus? Rheumatol Int 2006; 26(8):765–767PubMedCrossRefGoogle Scholar
  27. Lambotte O, Khellaf M, et al Characteristics and long-term outcome of 15 episodes of systemic lupus erythematosus-associated hemophago-cytic syndrome. Medicine (Baltimore) 2006; 85(3):169–182CrossRefGoogle Scholar
  28. Lawrence S, Luy L, et al The health of mothers of children with cutaneous neonatal lupus erythematosus differs from that of mothers of children with congenital heart block. Am J Med 2000; 108(9):705–709PubMedCrossRefGoogle Scholar
  29. ###.
    Lee LA, Sokol RJ, et al Hepatobiliary disease in neonatal lupus: prevalence and clinical characteristics in cases enrolled in a national registry. Pediatrics 2002; 109(1):E11PubMedCrossRefGoogle Scholar
  30. Martino D, Chew NK, et al Atypical movement disorders in antiphos-pholipid syndrome. Mov Disord 2006; 21(7):944–949PubMedCrossRefGoogle Scholar
  31. Massengill SF, Hedrick C, et al Antiphospholipid antibodies in pediat-ric lupus nephritis. Am J Kidney Dis 1997; 29(3):355–361PubMedCrossRefGoogle Scholar
  32. Nakahara C, Hayashi D, et al Delayed onset of systemic lupus erythe-matosus in a child with endothelial tubuloreticular inclusion. Clin Nephrol 2001; 56(4):332–335PubMedGoogle Scholar
  33. Nakayama-Furukawa F, Takigawa M, et al Hydrocephalus in two female siblings with neonatal lupus erythematosus. Arch Dermatol 1994; 130(9):1210–1212PubMedCrossRefGoogle Scholar
  34. Neiman AR, Lee LA, et al Cutaneous manifestations of neonatal lupus without heart block: Characteristics of mothers and children enrolled in a national registry. J Pediatr 2000; 137(5):674–680PubMedCrossRefGoogle Scholar
  35. Olfat MO, Al-Mayouf SM, et al Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus. Clin Rheumatol 2004; 23(5):395–399PubMedCrossRefGoogle Scholar
  36. Pluchinotta FR, Schiavo B, et al Distinctive clinical features of pediat-ric systemic lupus erythematosus in three different age classes. Lupus 2007; 16(8):550–555PubMedCrossRefGoogle Scholar
  37. Prendiville JS, Cabral DA, et al Central nervous system involvement in neonatal lupus erythematosus. Pediatr Dermatol 2003; 20(1):60–67PubMedCrossRefGoogle Scholar
  38. Press J, Palayew K, et al Antiribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. Arthritis Rheum 1996; 39(4):671–676PubMedCrossRefGoogle Scholar
  39. Pringe A, Trail L, et al Macrophage activation syndrome in juvenile systemic lupus erythematosus: An under-recognized complication? Lupus 2007; 16(8):587–592PubMedCrossRefGoogle Scholar
  40. Provost TT, Watson R, et al The neonatal lupus syndrome associated with U1RNP (nRNP) antibodies. N Engl J Med 1987; 316(18):1135–1138PubMedCrossRefGoogle Scholar
  41. Qian J, Yang CD. Hemophagocytic syndrome as one of main manifestations in untreated systemic lupus erythematosus: Two case reports and literature review. Clin Rheumatol 2007; 26(5):807–810PubMedCrossRefGoogle Scholar
  42. Rappaport KD, Tang WM. Herpes simplex virus type 2 acute retinal necrosis in a patient with systemic lupus erythematosus. Retina 2000; 20(5):545–546PubMedCrossRefGoogle Scholar
  43. Ruperto N, Ravelli A, et al The pediatric rheumatology international trials organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the definition of improvement. Arthritis Rheum 2006; 55(3):355–363PubMedCrossRefGoogle Scholar
  44. Sabbadini MG, Manfredi AA, et al Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsy-chiatric manifestations. Lupus 1999; 8(1):11–19PubMedCrossRefGoogle Scholar
  45. Sanna G, Bertolaccini ML, et al Neuropsychiatric manifestations in systemic lupus erythematosus: Prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30(5):985–992PubMedGoogle Scholar
  46. Sekigawa I, Nawata M, et al Cytomegalovirus infection in patients with systemic lupus erythematosus. Clin Exp Rheumatol 2002; 20(4):559–564PubMedGoogle Scholar
  47. Sheth AP, Esterly NB, et al U1RNP positive neonatal lupus erythema-tosus: Association with anti-La antibodies? Br J Dermatol 1995; 132(4):520–526PubMedCrossRefGoogle Scholar
  48. Su CT, Huang CB, et al Neonatal lupus erythematosus in association with anti-RNP antibody: A case report. Am J Perinatol 2001; 18(8):421–426PubMedCrossRefGoogle Scholar
  49. Sundgren PC, Jennings J, et al MRI and 2D-CSI MR spectroscopy of the brain in the evaluation of patients with acute onset of neuropsy-chiatric systemic lupus erythematosus. Neuroradiology 2005; 47(8):576–585PubMedCrossRefGoogle Scholar
  50. Taddio A, Brescia AC, et al Steady improvement of prothrombin levels after cyclophosphamide therapy in pediatric lupus anticoagulant hypoprothrombinemia syndrome (LAHPS). Clin Rheumatol 2007; (12):2167–2169Google Scholar
  51. Takei M, Yamakami K, et al A case of systemic lupus erythematosus complicated by alveolar hemorrhage and cytomegalovirus colitis. Clin Rheumatol 2007; 26(2):274–277PubMedCrossRefGoogle Scholar
  52. Thornton CM, Eichenfield LF, et al Cutaneous telangiectases in neonatal lupus erythematosus. J Am Acad Dermatol 1995; 33(1):19–25PubMedCrossRefGoogle Scholar
  53. Uthman I, Khalil I, et al Lupus anticoagulant, factor V Leiden, and meth-ylenetetrahydrofolate reductase gene mutation in a lupus patient with cerebral venous thrombosis. Clin Rheumatol 2004; 23(4):362–363PubMedCrossRefGoogle Scholar
  54. Verdolini R, Bugatti L, et al Systemic lupus erythematosus induced by Epstein-Barr virus infection. Br J Dermatol 2002; 146(5):877–881PubMedCrossRefGoogle Scholar
  55. Vyas S, Hidalgo G, et al Outcome in African-American children of neuropsychiatric lupus and lupus nephritis. Pediatr Nephrol 2002; 17(1):45–49PubMedCrossRefGoogle Scholar
  56. Waltuck J, Buyon JP. Autoantibody-associated congenital heart block: Outcome in mothers and children. Ann Intern Med 1994; 120(7):544–551PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Earl D. Silverman
    • 1
  1. 1.Pediatrics, Division of Rheumatology, Hospital for Sick ChildrenUniversity of TorontoTorontoCanada

Personalised recommendations